RxDoctor Payments Data

Laura Sherrill, MD

Urology · Wausau, WINPI 1417985805

Payments from drug & device makers

$711in general payments, 2019–2025

Across 24 payments — averaging $29.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$172
  • Medtronic$140
  • AbbVie$111
  • Procept Biorobotics Corporation$108
  • Olympus America Inc.$47
  • BD$36
  • plus $97 from 4 others

What the payments were for

  • Food & beverage$55678%
  • Education$15522%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$711 in reported general payments places this provider in the 45th percentile of 215 urology providers in Wisconsin.

See all urology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$179,191
Medicare patients
269
Services billed
10,737

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron79$48,603
GemtesaVibegron79$44,221
Estradiol20$2,454
Oxybutynin Chloride ErOxybutynin Chloride42$1,376
Tamsulosin Hcl137$1,217
Solifenacin Succinate38$820
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst42$763
Potassium Citrate ErPotassium Citrate12$515
Oxybutynin Chloride78$480
Imipramine Hcl12$330
Cephalexin48$280
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen93$179
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim49$165
Cefdinir11$150
Levofloxacin25$61

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$172$48,60379 claims
Sumitomo Pharma America, Inc.Gemtesa$27$44,22179 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 215 urology providers in Wisconsin.

Other urology in Wausau

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →